Gilead’s Lenacapavir Shows Promise in Preventing HIV Infection

Key Takeaways

• A Phase 3 trial of Gilead’s injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women.
• Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.
• More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.
• Shares of Gilead surged Thursday following the news.

Gilead Sciences experienced a significant surge in its stock price on Thursday as the biotech firm announced promising results from a Phase 3 trial of its injectable drug lenacapavir. The trial revealed that lenacapavir was 100% effective in preventing HIV infection in women, marking a significant breakthrough in HIV prevention research.

The results were so compelling that the independent Data Monitoring Committee (DMC) recommended that Gilead end the blind phase of the study and offer lenacapavir to all participants. This recommendation speaks to the strength of the data and the potential impact of lenacapavir in preventing HIV transmission.

### Zero HIV Infections Among Women Who Took Gilead’s Lenacapavir

The Phase 3 trial conducted by Gilead found zero cases of HIV infection among the 2,134 women who received lenacapavir. In contrast, several cases of HIV infection were reported among those who took Gilead’s current HIV pills, Truvada and Descovy. Truvada was the first pre-exposure prophylaxis (PrEP) treatment approved by the Food and Drug Administration (FDA), making the effectiveness of lenacapavir even more remarkable.

### More Testing Needed Before Applying for FDA Approval

While the results from the trial are promising, Gilead must conduct additional testing before applying for FDA approval. The company plans to run another Phase 3 test of lenacapavir in men who have sex with men and other at-risk groups. These results are expected later this year or early next year and will be crucial in determining the drug’s overall efficacy and safety profile.

Dr. Linda-Gail Bekker, head of the Desmond Tutu HIV Center at the University of Cape Town, South Africa, and former president of the International AIDS Society, expressed optimism about lenacapavir’s potential impact on HIV prevention. She believes that lenacapavir could offer a critical new choice for HIV prevention that aligns with the needs of individuals who could benefit from PrEP worldwide.

Following the announcement of the trial results, Gilead’s stock price surged by 8.2% to $68.31 as of 3 p.m. ET on Thursday. Despite this positive development, Gilead Sciences has seen a decline of close to 16% in its stock value this year, reflecting broader market trends and investor sentiment.


In conclusion, Gilead’s lenacapavir has shown great promise in preventing HIV infection, particularly among women. The company’s commitment to further testing and regulatory approval underscores its dedication to advancing HIV prevention strategies and improving public health outcomes. As additional data becomes available, stakeholders will closely monitor Gilead’s progress towards bringing this innovative drug to market and potentially transforming the landscape of HIV prevention efforts globally.

**Read the original article on [Investopedia](https://www.investopedia.com/gilead-stock-surges-on-strong-results-in-hiv-drug-study-8666588).**